

24 February 2026

## Annual Financial Report

AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2025 (the Annual Report).

A copy of the Annual Report will be submitted to the National Storage Mechanism and will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The Annual Report is also available on the Company's website [www.astrazeneca.com](http://www.astrazeneca.com).

The Annual Report will be dispatched to shareholders in due course.

The Company's Annual General Meeting (AGM) will take place on 9 April 2026. The Notice of AGM and Shareholders' Circular will be published and distributed to shareholders in due course.

### EXPLANATORY NOTE

For the purposes of complying with the Disclosure and Transparency Rules, the Annual Report being submitted to the National Storage Mechanism contains the following regulated information in unedited form:

- the principal risks and uncertainties facing the Company;
- the Directors' responsibility statement made in respect of the Financial Statements and Directors' Report contained in the Annual Report; and
- a statement regarding related party transactions.

### [AstraZeneca](#)

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit [astrazeneca.com](http://astrazeneca.com) and follow the Company on Social Media [@AstraZeneca](#).

### Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

**Matthew Bowden**  
Company Secretary  
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSPUMWUPQGBW